Encompass Health, Enhabit Secure $43.1M Judgement in VitalCaring Case
Encompass Health and Enhabit Inc. have been awarded $43.1 million in a judgement against home health and hospice provider VitalCaring. This ruling mandates that 43% of VitalCaring's profits and future sale proceeds be placed in a trust for Encompass and Enhabit, stemming from allegations of misconduct by VitalCaring's senior executives who previously worked for Encompass Health. The dispute had also paused VitalCaring's acquisition of over 100 home health and hospice locations.
Enhabit Home Health & Hospice Data Breach Lawsuit Investigation
Shamis & Gentile P.A. is investigating a data breach affecting Enhabit Home Health & Hospice, where an unauthorized party accessed patient information through a compromised Doctor Alliance account between October and November 2025. The breach, which impacted 22,552 individuals, exposed names, addresses, dates of birth, genders, physician names, medical record numbers, certain clinical information, and health plan numbers, though no Social Security numbers or financial information were compromised. Affected individuals may be entitled to compensation and are encouraged to join the class action lawsuit.
Enhabit, Encompass Health Collect $43.1M From VitalCaring Case
Encompass Health and Enhabit Inc. have collected $43.1 million in attorneys’ fees and mitigation damages from a profit-sharing case against VitalCaring. This settlement stemmed from a federal judge's order allocating 43% of VitalCaring's profits and any exit proceeds to Encompass and Enhabit, due to "willful misconduct" by former senior officers of Encompass Health’s home health and hospice division. The misconduct involved the alleged use of unethical practices by April Anthony, Luke James and Chris Walker to establish VitalCaring.
Enhabit and Encompass Health Collect $43.1 Million from Individual Defendants in Delaware Fiduciary Breach Case
Enhabit, Inc. and Encompass Health Corporation have successfully collected $43.1 million from former officers and partners in full satisfaction of claims for attorneys’ fees and mitigation damages in a Delaware fiduciary breach case. This settlement follows a December 2024 judgment that found "egregious breaches of the duty of loyalty" by April Anthony, Luke James, and Chris Walker. The companies will also split 43% of VitalCaring Group's ongoing profits and exit proceeds via a constructive trust.
Enhabit, Encompass Health Collect $43.1 Million from Individual Defendants in Delaware Fiduciary Breach Case
Enhabit, Inc. (EHAB) and Encompass Health Corporation (EHC) have successfully collected $43.1 million in a Delaware fiduciary breach case against former officers and partners. This settlement fully satisfies their claims for attorney's fees and mitigation damages. Additionally, the companies will receive 43% of VitalCaring Group’s ongoing profits and exit proceeds through a constructive trust.
Enhabit (EHAB) price target increased by 10.85% to 11.98
This article announces that the price target for Enhabit (EHAB) has been increased by 10.85% to $11.98. The content for the article is not provided beyond the title.
Enhabit Home Health & Hospice Announces Date of 2025 Fourth Quarter Earnings Call
Enhabit, Inc. (NYSE: EHAB) announced it will report its financial results for the fourth quarter and fiscal year ended December 31, 2025, on March 4, 2026. The company will also host a webcast and conference call on March 5, 2026. Enhabit is a national home health and hospice provider with a footprint across 34 states.
Enhabit Home Health & Hospice Announces Date of 2025 Fourth Quarter Earnings Call
Enhabit, Inc. (NYSE: EHAB) announced it will release its financial results for the fourth quarter and fiscal year ending December 31, 2025, on March 4, 2026. The company will host a webcast and conference call on March 5, 2026, at 9 a.m. EST to discuss these results. Details for joining the call, including dial-in numbers and a webcast link, have been provided.
Enhabit Secures $43.1 Million in Delaware Legal Settlement
Enhabit, Inc., along with Encompass Health Corporation, has secured $43.1 million in damages from a Delaware Court of Chancery ruling concerning fiduciary breaches by former officers. This settlement fully satisfies claims for attorneys' fees and mitigation damages. Additionally, a constructive trust was imposed, granting Enhabit and Encompass Health a 43% share of VitalCaring Group’s ongoing profits and future sale proceeds, providing potential further financial upside.
Enhabit and Encompass Health Collect $43.1 Million from Individual Defendants in Delaware Fiduciary Breach Case
Enhabit and Encompass Health have successfully collected $43.1 million from individual defendants Chris Walker, David Schuppan, and Christopher Corey in a Delaware fiduciary breach case. This settlement fully satisfies their claims for attorneys' fees and mitigation damages, stemming from a December 2024 judgment that found "egregious breaches of the duty of loyalty." The companies will also split 43% of VitalCaring Group’s ongoing profits and exit proceeds through a constructive trust.
Enhabit, Inc. (NYSE:EHAB) Given Consensus Recommendation of "Moderate Buy" by Analysts
Analysts have given Enhabit, Inc. (NYSE:EHAB) a consensus rating of "Moderate Buy," with an average 12-month price target of $12.10. Recent analyst actions include reinitiating "buy" ratings and upgrading the stock. Enhabit's stock has shown recent gains, and hedge funds have adjusted their positions in the company.
Enhabit, Inc. $EHAB Shares Purchased by Y Intercept Hong Kong Ltd
Y Intercept Hong Kong Ltd significantly increased its stake in Enhabit, Inc. (NYSE:EHAB) by 188.2% in the third quarter, acquiring an additional 142,556 shares to hold a total of 218,284 shares valued at $1.748 million. This comes as analyst sentiment for Enhabit has turned positive, with six Buy ratings, one Hold, and one Sell, leading to a consensus "Moderate Buy" rating and a target price of $12.10. Enhabit also reported beating Q3 earnings expectations and issued optimistic FY2025 EPS guidance.
Enhabit, Inc. (EHAB) Stock Analysis: Is A 11.48% Upside Worth The Investment?
Enhabit, Inc. (EHAB), a healthcare company specializing in home health and hospice services, is currently trading at $10.54 with a potential upside of 11.48% based on analyst target prices. Despite facing challenges with a negative EPS and ROE, the company shows stability with a robust free cash flow of $50.94 million and a bullish technical outlook, trading above its 50-day and 200-day moving averages. Enhabit's strategic focus in the growing at-home care sector positions it for potential growth, making it a compelling consideration for investors despite its current financial performance challenges.
Enhabit, Inc. (EHAB) Stock Analysis: Exploring A 5.39% Potential Upside In Healthcare
Enhabit, Inc. (EHAB), a healthcare provider specializing in home health and hospice services, is showing a potential upside of 5.39% according to analyst targets, with a current stock price of $11.07. Despite positive analyst sentiment and revenue growth of 3.90%, the company faces profitability challenges as indicated by negative EPS and ROE. Investors are optimistic about Enhabit's future earnings improvement and strategic expansion in comprehensive care services for an aging population.
Enhabit (NYSE:EHAB) Sets New 52-Week High - What's Next?
Enhabit (NYSE:EHAB) recently hit a new 52-week high, trading at $11.35 on a volume of 159,660 shares, and is currently above its 50-day and 200-day moving averages. The company reported strong quarterly earnings, beating EPS estimates, and has a "Moderate Buy" consensus rating from analysts with an average price target of $12.10. Several hedge funds have also increased their stakes in Enhabit, a national provider of home-based healthcare services.
Do Enhabit (EHAB) Analyst Upgrades Hint At A Stronger Reimbursement And Growth Narrative?
Recently, TD Cowen and UBS upgraded Enhabit (EHAB) to Buy, indicating a reassessment of the home health and hospice provider's risk-reward profile by large institutions. This shift suggests renewed analyst confidence, particularly concerning Enhabit's reimbursement resilience and growth prospects, with the company's 2025 guidance for net service revenue providing a key reference point for investors. Despite the positive analyst sentiment, investors are advised to consider the risks of future Medicare rate decisions and various valuation perspectives.
Do Enhabit (EHAB) Analyst Upgrades Hint At A Stronger Reimbursement And Growth Narrative?
Recent analyst upgrades for Enhabit (EHAB) by TD Cowen and UBS to "Buy" suggest a re-evaluation of the home health and hospice provider's risk-reward profile amidst its changing operating environment. These upgrades indicate growing confidence in Enhabit's ability to navigate reimbursement pressures and translate demand into profitability. Investors should consider Enhabit's updated 2025 revenue guidance and compare various valuation perspectives, as projections for the company's future revenue and earnings (reaching $1.2 billion and $22.3 million by 2028, respectively) imply a fair value of $10.60, aligning with its current price.
Enhabit (NYSE:EHAB) Reaches New 52-Week High on Analyst Upgrade
Enhabit (NYSE:EHAB) recently hit a new 52-week high after Deutsche Bank upgraded the stock to a "buy" rating. The company's stock traded as high as $11.27, up from its prior close of $10.19, reflecting a generally positive analyst outlook with a "Moderate Buy" average rating and a consensus target price of $11.63. Despite a negative P/E ratio, Enhabit beat EPS estimates in its last earnings report and provided positive FY2025 guidance.
Enhabit (NYSE:EHAB) Upgraded to Buy at TD Cowen
Enhabit (NYSE:EHAB) has been upgraded from a "hold" to a "buy" rating by TD Cowen, with a new price target of $12.00, suggesting a potential 17.91% upside. This upgrade aligns with a generally positive analyst outlook, resulting in a "Moderate Buy" consensus rating and an average target price of $11.63 from other analysts. The company recently surpassed quarterly EPS estimates and provided optimistic FY2025 guidance.
Enhabit, Inc. (NYSE:EHAB) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Enhabit, Inc. (NYSE:EHAB) has received a "Moderate Buy" consensus recommendation from brokerages, with an average 12-month target price of $11.50. This comes after UBS and Cowen recently upgraded the stock. Despite this, the company reported mixed Q4 earnings, beating EPS estimates but slightly missing on revenue, and provided FY2025 EPS guidance of $0.500-$0.560.
Enhabit upgraded to Buy from Hold at TD Cowen
TD Cowen analyst Ryan Langston upgraded Enhabit (EHAB) to Buy from Hold, increasing the price target to $12 from $9. The upgrade is attributed to an improving home health regulatory environment and the expectation of a positive earnings revision cycle for Enhabit due to its volume growth durability. Langston also noted that the company's regulatory overhang has been "de-risked."
Zacks Industry Outlook Highlights Medpace, Enhabit and Progyny
Zacks Equity Research highlights Medpace Holdings (MEDP), Enhabit, Inc. (EHAB), and Progyny (PGNY) as key players in the rapidly evolving Medical Services sector. The industry is driven by digital health advances, value-based care, and patient-centric solutions, facing trends such as digital transformation and a continuing healthcare staffing shortage. Despite a "Dull Prospects" industry rank according to Zacks, these three companies are identified as having strong earnings outlooks and are positioned to benefit from market shifts.
Insiders Buying Enhabit Might Wish They Invested More, Stock Gains 11%
Insiders at Enhabit, Inc. who bought shares in the past year have seen a 33% return on their investment after the stock rose 11%. Chief Financial Officer Ryan Solomon made the largest insider purchase of US$76k worth of shares at a price well below the current market value, suggesting he viewed the stock as undervalued. Despite no recent insider trading in the last quarter, insiders generally show an appetite for the stock and hold a 3.7% ownership in the company.
Insiders Buying Enhabit Might Wish They Invested More, Stock Gains 11%
Insiders at Enhabit, Inc. who purchased shares over the past year have seen a 33% gain on their initial investment, with the stock rising 11% last week. Chief Financial Officer Ryan Solomon's purchase of US$76k worth of shares at a lower price suggests insiders viewed the stock as undervalued. Insider ownership stands at 3.7%, indicating a reasonable alignment of interests.
Enhabit upgraded to Buy from Neutral at UBS
UBS analyst AJ Rice has upgraded Enhabit (EHAB) from Neutral to Buy, increasing the price target to $12 from $8.50. This upgrade is based on increased clarity regarding Enhabit's future earnings outlook following the final home health rule and the stock's current "discounted valuation."
UBS Upgrades Enhabit (EHAB)
UBS has upgraded its outlook for Enhabit (EHAB) from Neutral to Buy. Despite the upgrade, the average one-year price target suggests a 2.31% downside from its current price. Institutional ownership in Enhabit remains significant, with several large funds holding substantial positions.
UBS upgrades Enhabit Home Health & Hospice stock rating to Buy on favorable Medicare rule
UBS has upgraded Enhabit Home Health & Hospice (NYSE:EHAB) from Neutral to Buy, raising its price target to $12.00 from $8.50. This decision follows a favorable final Medicare rule, which includes a significantly smaller rate cut than initially proposed. The improved clarity on future earnings and a discounted valuation were key factors in the upgrade.
Enhabit (NYSE:EHAB) Updates FY 2025 Earnings Guidance
Enhabit (NYSE:EHAB) has released its FY 2025 earnings guidance, projecting EPS between $0.500 and $0.560 and revenue of $1.1 billion, aligning with consensus estimates. The company recently reported Q3 results that surpassed EPS expectations but slightly missed on revenue, with a negative net margin. Analysts currently have a "Hold" rating on EHAB stock with a consensus target price of $8.50.
Enhabit (EHAB) Shows Fast-paced Momentum But Is Still a Bargain Stock
Enhabit (EHAB) is identified as a bargain stock exhibiting fast-paced momentum, making it an attractive investment according to the "Fast-Paced Momentum at a Bargain" screen. The company shows recent stock price gains of 7.7% over four weeks and 16.7% over 12 weeks, with a high beta of 1.67, indicating strong momentum. Furthermore, EHAB holds a Zacks Rank #2 (Buy) and is considered undervalued with a Price-to-Sales ratio of 0.45.
Is Enhabit, Inc. (EHAB) Stock Outpacing Its Medical Peers This Year?
Enhabit (EHAB) is outperforming its Medical sector peers and the Medical Services industry year-to-date, with a 23.2% gain compared to the sector's 5.8% average rise. The stock holds a Zacks Rank #2 (Buy), driven by a 12.4% increase in its full-year earnings consensus estimate over the past three months. Another strong performer in the Medical sector is Gain Therapeutics, Inc. (GANX), which is up 87.5% year-to-date.
Enhabit price target raised to $12 from $11 at Jefferies
Jefferies has raised its price target for Enhabit (EHAB) to $12 from $11, maintaining a A Buy rating on the shares. This adjustment comes after gaining clarity on the CMS home health rule, which provides improved reimbursement visibility for the company. The firm also cited Enhabit's ongoing cost savings initiatives as a reason for its continued positive outlook.
Home health companies are pushing for value-based care contracts
Home health companies such as Bayada, Enhabit, and Compassus are actively pursuing value-based care contracts to engage in shared cost-savings deals. This push indicates a shift in the home healthcare industry towards models that prioritize efficiency and cost-effectiveness. The article highlights this trend within the post-acute care sector.
Globeflex Capital L P Takes Position in Enhabit, Inc. $EHAB
Globeflex Capital L P has acquired a new stake in Enhabit, Inc. (NYSE:EHAB), purchasing 119,716 shares valued at approximately $1.154 million. This move represents about 0.24% of the company as Enhabit reported stronger-than-expected EPS for the last quarter and provided positive FY2025 guidance. Despite a negative net margin, the company maintains a positive return on equity, and analysts currently rate the stock as "Hold" with a target price of $8.50.
Enhabit’s Double-Pronged Growth Outlook for 2026
Enhabit Inc. has focused its resources on organic growth and de novos rather than acquisitions due to high hospice multiples, but anticipates increased opportunities for strategic M&A in 2026. The company is on track to open 10 new locations in 2025 and utilizes a colocation strategy to build brand recognition in markets where it already has home health services. This dual approach aims to balance disciplined growth with potential strategic acquisitions as market conditions evolve.
Enhabit, Inc to Present at 2025 Home Care Conference
Enhabit, Inc. announced its participation in the BofA Securities 2025 Home Care Conference to discuss strategic focuses and business developments, anticipating growth with improved financial metrics and clarity on reimbursement rates for 2026 and beyond. Despite a neutral rating from TipRanks' AI Analyst, the company's strong earnings call performance and positive technical indicators are noted, alongside profitability and valuation challenges. The most recent analyst rating on EHAB stock is a Hold with a $9.50 price target.
Enhabit, Inc. (EHAB) Presents at Bank of America Home Care Conference - Slideshow (NYSE:EHAB) 2025-12-10
Enhabit, Inc. (EHAB) presented a slideshow at the Bank of America Home Care Conference. The article shared that Enhabit, Inc. published the slide deck in conjunction with this event. The content is provided by SA Transcripts, Seeking Alpha's transcripts team.
Enhabit (NYSE: EHAB) outlines strategy and 2026 pricing at BofA conference
Enhabit, Inc. (NYSE: EHAB) announced its participation in the BofA Securities 2025 Home Care Conference on December 9, 2025. President and CEO Barbara Jacobsmeyer and CFO Ryan Solomon will discuss the company's strategic focus, recent business developments, and anticipated pricing impacts for 2026. An investor presentation will accompany their fireside chat, providing detailed insights into these topics.
Enhabit, Inc. Discusses Strategic Focus at BofA Securities Conference
Enhabit, Inc. participated in the BofA Securities 2025 Home Care Conference, where its CEO and CFO highlighted the company's strategic focus and business developments. They also discussed anticipated pricing impacts for 2026, updating that the final CMS rule narrows the 2026 rate headwind to $6M-$8M, and reiterated 2025 guidance with net service revenue of $1,058M-$1,063M. The company projects mid-to-high single digit admission growth for 2026.
Enhabit, Inc to Present at 2025 Home Care Conference
Enhabit, Inc. (EHAB) will discuss its strategic focuses and business development at the BofA Securities 2025 Home Care Conference. The company, operating in home health and hospice, aims for growth through new locations and acquisitions, with executives highlighting improved financial metrics and clearer reimbursement rates. Despite a "Hold" rating from analysts with a $9.50 price target and Spark’s AI Analyst noting mixed financial performance, Enhabit anticipates enhanced investment opportunities in 2026 and beyond.
Enhabit Inc. Reports Strong Q3 Earnings Amid Challenges
Enhabit Inc. has reported robust Q3 earnings, demonstrating strong financial performance despite ongoing challenges in the healthcare sector. The company's results highlight its resilience and strategic effectiveness in navigating economic headwinds. This positive earnings report should instill confidence in investors and stakeholders regarding Enhabit's operational stability and future growth trajectory.
Enhabit Inc. Reports Strong Q3 Earnings Amid Challenges
The provided article content was "MSN", which is insufficient to generate a summary or extract meaningful information about Enhabit Inc.'s Q3 earnings. There is no actual financial data, company performance details, or specific challenges mentioned.
Enhabit Announces Participation in Bank of America Home Care Conference 2025
Enhabit, Inc. announced its participation in the Bank of America Home Care Conference 2025. President and CEO Barb Jacobsmeyer and CFO Ryan Solomon will participate in a fireside chat on December 9th at 2:50 p.m. CT, which will be webcast live and available for replay. The event details can also be found on Enhabit's investor website.
Paradice Investment Management LLC Sells 33,274 Shares of Enhabit, Inc. $EHAB
Paradice Investment Management LLC has reduced its stake in Enhabit, Inc. (NYSE:EHAB) by 1.9%, selling 33,274 shares and retaining 1,736,964 shares valued at $16.74 million. Despite this, Enhabit remains Paradice's 15th largest holding, representing about 3.4% of its portfolio. Other institutional investors like 8 Knots Management LLC and Vanguard Group Inc. increased their positions, while Iron Triangle Partners LP opened a new significant stake.
Connor Clark & Lunn Investment Management Ltd. Purchases Shares of 89,032 Enhabit, Inc. $EHAB
Connor Clark & Lunn Investment Management Ltd. has acquired a new stake of 89,032 shares in Enhabit, Inc. for approximately $858,000 during the second quarter. Other institutional investors also adjusted their positions in EHAB, with notable increases from 8 Knots Management LLC, Vanguard Group Inc., and DekaBank Deutsche Girozentrale. Analysts currently rate Enhabit as a "Hold" with a consensus target price of $9.00.
What To Expect From Enhabit Inc (EHAB) Q3 2025 Earnings
Enhabit Inc (EHAB) is projected to release its Q3 2025 earnings on November 5, 2025, with expected revenue of $267.18 million and EPS of $0.11. Analyst price targets suggest an average upside of 12.82% from its current price, while GuruFocus estimates a 28.04% upside. The company's average brokerage recommendation is a "Hold" based on five firms.
Enhabit Reports Third Quarter 2025 Financial Results
Enhabit, Inc. announced strong third-quarter 2025 financial results, showing significant year-over-year growth in revenue, census, and Adjusted EBITDA, totaling $263.6 million in net service revenue and $27.0 million in Adjusted EBITDA. The company also reduced bank debt for the seventh consecutive quarter, strengthening its balance sheet. CEO Barb Jacobsmeyer highlighted strong execution on core strategic priorities and updated guidance for 2025.
Hospice De Novos Fueling Enhabit’s Growth
Enhabit Inc. (NYSE: EHAB) is experiencing significant growth, driven largely by its hospice de novo strategy and organic expansion. The company is on track to open 10 new locations in 2025, with its seventh having opened in October. These efforts led to strong third-quarter results in 2025, with net service revenue of $263.6 million and a nearly 20% increase in its hospice segment revenue year-over-year.
Enhabit Bets On Mitigation Strategies To Counter Negative Impacts Of Proposed Payment Rule
Enhabit Inc. is implementing mitigation strategies, such as advanced visit-per-episode management, to counter the negative impacts of potential Medicare payment rule changes and other industry headwinds. Despite concerns about the proposed 2026 Medicare payment rule, the company reported record revenues and profitability in Q3, attributing success to operational execution, payer innovation, and de novo growth strategies. Enhabit's leadership is advocating for CMS to reverse proposed cuts to ensure continued patient access to home health care, maintaining confidence in their ability to manage challenges and grow market share.
Enhabit Home Health & Hospice Announces Date of 2025 Third Quarter Earnings Call
Enhabit, Inc. (NYSE: EHAB) announced it will report its financial results for the third quarter ended Sept. 30, 2025, on Nov. 5, 2025. The company will host a webcast and conference call on Nov. 6, 2025, to discuss these results. Details for participating in the call, including call-in numbers and webcast link, are provided.
EHAB Stock Price and Chart — NYSE:EHAB
This page provides a comprehensive overview of Enhabit, Inc. (EHAB) stock, including real-time pricing, key financial statistics, and performance charts. It also features fundamental company information, analyst ratings, and technical indicators to help investors assess the stock's outlook.
